IP Library Granted Patent US 8,277,793
Granted Patent B2
US 8,277,793 · App. 12/307,726 · Granted Oct 2, 2012

Prophylactic or therapeutic agent for viral disease

Assignee: Meiji Seika Pharma Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,277,793
App. No.
12/307,726
Granted
Oct 2, 2012
Kind
B2
Abstract

A prophylactic or therapeutic agent for a viral disease, characterized by combining 22β-methoxyolean-12-ene-3β,24(4β)-diol with an interferon as active ingredients is disclosed. The prophylactic or therapeutic agent of the present invention exhibits a high therapeutic effect by administering 22β-methoxyolean-12-ene-3β,24(4β)-diol and interferon as a combination thereof.

Claims (6)

1. A pharmaceutical composition, comprising 22β-methoxyolean-12-ene-3β,24(4β)-diol and an interferon α.

2. The pharmaceutical composition according to claim 1 , wherein the interferon α is at least one IFNα selected from the group consisting of natural IFNα, IFNα-2a, IFNα-2b, PEG-natural IFNα, PEG-IFNα-2a and PEG-IFNα-2b.

3. The pharmaceutical composition according to claim 1 , wherein the composition is a single preparation comprising the combination of 22β-methoxyolean-12-ene-3β,24(4β)-diol and the interferon α.

4. The pharmaceutical composition according to claim 1 , wherein the composition is a combination of a first single preparation comprising the 22β-methoxyolean-12-ene-3β,24(4β)-diol and a second single preparation comprising the interferon α.

5. The pharmaceutical composition according to claim 3 , wherein the 22β-methoxyolean-12-ene-3β,24(4β)-diol and the interferon α are in a combination ratio from 1 mg:100,000 I.U. to 1000 mg:10,000,000 I.U.

6. The pharmaceutical composition according to claim 5 , wherein the 22β-methoxyolean-12-ene-3β,24(4β)-diol and the interferon α are in a combination ratio from 25 mg:1,000,000 I.U. to 800 mg:10,000,000 I.U.

Assignments (2)
CHANGE OF NAME Recorded Jun 5, 2012
From: MEIJI SEIKA KAISHA, LTD.
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 028324/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2009
From: HIASA, YOICHI; KUZUHARA, HIROYUKI
To: MEIJI SEIKA KAISHA, LTD.
Reel/Frame 022920/0496 →
Priority Claims (1)
JP 2006-187943 · Jul 7, 2006 · national
Continuity (1)
Related Publication 20090324541A1 · Dec 31, 2009